Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect

Koike, Terumoto; Qutab, Muhammad Nadeen; Tsuchida, Masanori; Takekubo, Masaru; Saito, Masayuki; Hayashi, Jun‐Ichi

doi:10.1016/j.pupt.2007.01.007

Cited by 14 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the therapy was initiated before weaning from CPB, a highly significant decrease in postoperative low cardiac output state was observed . In addition to their inotropic effect, these drugs have a peripheral vasodilator effect and an anti‐inflammatory effect, the exact mechanism of which is still unclear . Trying to determinate precisely how much each of the three effects contributes to the improvement in clinical outcome seems rather utopian.…”

Section: Pulsatile Flowmentioning

confidence: 99%

Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population

Durandy

2013

Artificial Organs

View full text Add to dashboard Cite

Cardiopulmonary bypass (CPB) is known to cause a systemic inflammatory response. Inflammation includes several cascade activations: complement, cytokine, and coagulation. The early phase is triggered by blood contact with the synthetic bypass circuit and the late phase by ischemia-reperfusion and endotoxemia. Systemic inflammatory response syndrome (SIRS) is constant following cardiac surgery; however, a compensatory anti-inflammatory response is also constant and the clinical manifestations (varying from uncomplicated SIRS to shock and multiple organ dysfunction) depend on the balance between the two responses. When overexpressed, the inflammatory response may significantly increase a patient's risk. Minimization of systemic inflammation is a major concern and several strategies aiming to inhibit the inflammatory response are described. None of them is satisfactory, but the "control" of the inflammatory response extent is likely to require a multimodal approach. This review aims to describe the strategies proposed to reduce CPB-related systemic inflammation.

show abstract

Section: Pulsatile Flowmentioning

confidence: 99%

Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population

Durandy

2013

Artificial Organs

View full text Add to dashboard Cite

show abstract

“…28 Some studies have shown that an increased infl ammatory response correlates with the incidence of early postoperative AF. 29 It has been reported that olprinone showed antiinfl ammatory eff ects in experimental models of myocardial ischemia-reperfusion injury, 30 lipopolysaccharide-induced lung injury, 31 ischemiareperfusion-induced acute renal injury, 16 and endotoxic shock. 32 In the present study, patients in the olprinone group showed signifi cantly lower WBC counts and CRP levels aft er surgery compared with the placebo group.…”

Section: Discussionmentioning

confidence: 99%

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

Nojiri

Yamamoto

Maeda

et al. 2015

Chest

View full text Add to dashboard Cite

“…However, increasing cAMP PDE3 inhibitors may also modulate an inflammation. Pretreatment with olprinone in a rat model of LPS-induced endotoxemia inhibited neutrophil influx into the lung, suppressed pro-inflammatory cytokines TNFα and IL-6, and increased anti-inflammatory cytokine IL-10 [137]. Olprinone given immediately after induction of sepsis in mice prevented a development of sepsis-associated ALI and improved a survival of septic animals [138].…”

Section: Pde3 Inhibitorsmentioning

confidence: 98%

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Mokrá

Mokrý

2021

IJMS

View full text Add to dashboard Cite

Despite progress in understanding the pathophysiology of acute lung damage, currently approved treatment possibilities are limited to lung-protective ventilation, prone positioning, and supportive interventions. Various pharmacological approaches have also been tested, with neuromuscular blockers and corticosteroids considered as the most promising. However, inhibitors of phosphodiesterases (PDEs) also exert a broad spectrum of favorable effects potentially beneficial in acute lung damage. This article reviews pharmacological action and therapeutical potential of nonselective and selective PDE inhibitors and summarizes the results from available studies focused on the use of PDE inhibitors in animal models and clinical studies, including their adverse effects. The data suggest that xanthines as representatives of nonselective PDE inhibitors may reduce acute lung damage, and decrease mortality and length of hospital stay. Various (selective) PDE3, PDE4, and PDE5 inhibitors have also demonstrated stabilization of the pulmonary epithelial–endothelial barrier and reduction the sepsis- and inflammation-increased microvascular permeability, and suppression of the production of inflammatory mediators, which finally resulted in improved oxygenation and ventilatory parameters. However, the current lack of sufficient clinical evidence limits their recommendation for a broader use. A separate chapter focuses on involvement of cyclic adenosine monophosphate (cAMP) and PDE-related changes in its metabolism in association with coronavirus disease 2019 (COVID-19). The chapter illuminates perspectives of the use of PDE inhibitors as an add-on treatment based on actual experimental and clinical trials with preliminary data suggesting their potential benefit.

show abstract

Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect

Cited by 14 publications

References 26 publications

Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population

Minimizing Systemic Inflammation During Cardiopulmonary Bypass in the Pediatric Population

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?

Contact Info

Product

Resources

About